AstraZeneca’s antibody cocktail therapy successful at preventing COVID-19: Study
AstraZeneca, a UK-based biopharmaceutical company, on August 20, 2021, announced that its PROVENT Phase-III prophylaxis trial of its antibody cocktail therapy AZD7442, a combination of two long-acting antibodies (LAAB), met…